Amdocs Ltd (NASDAQ:DOX) director and officer Shimie Hortig has sold a total of $381,130 worth of the company's ordinary shares, according to a recent disclosure. The transactions were carried out over two consecutive trading days, November 10 and November 11, 2026.
Mr. Hortig disposed of 8,997 ordinary shares in total, with sale prices ranging between $42.1763 and $43.14 per share. On November 10, 2026, 7,264 shares were sold at a price of $42.1763 each. The following day, November 11, 2026, an additional 1,733 shares were sold at $43.14 per share. Following these transactions, Mr. Hortig directly holds 172,699 ordinary shares in Amdocs.
The insider sale comes as Amdocs shares trade at $44.79, down over 42% year-to-date and well below the 52-week high of $84.95. According to InvestingPro analysis, the stock appears undervalued at current levels, with a P/E ratio of 9.53 and a dividend yield of 5.08%. InvestingPro Tips highlight that the stock has fared poorly recently, though the company maintains strong fundamentals. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for DOX and 1,400+ other US equities.
In other recent news, Amdocs reported its fiscal fourth-quarter results, meeting Wall Street's expectations with non-GAAP earnings of $1.98 per share and revenue of $1.19 billion. However, the company's outlook for fiscal 2027 has raised concerns among investors. Amdocs anticipates a significant decline in both revenue and profit due to a dispute with a major customer, T-Mobile. This development has led to Oppenheimer downgrading Amdocs' stock rating from Outperform to Perform, citing weak guidance for fiscal 2027. Previously, Amdocs reported fiscal 2026 revenue of $4.7 billion, a 3.6% increase, and non-GAAP earnings per share of $7.41, up 6%, both aligning with expectations. These recent developments have captured the attention of investors and analysts alike, with a focus on the company's future performance amid ongoing challenges.
The sale by Mr. Hortig represents a notable insider transaction at a time when Amdocs shares are under pressure. While insider sales can occur for a variety of reasons, they are closely monitored by market participants for signals about management's confidence. The company's stock has declined sharply year-to-date, and the fiscal 2027 guidance has added to investor unease. Amdocs continues to navigate a challenging environment, with the dispute with T-Mobile casting a shadow over its near-term prospects. The company's strong fundamentals, as noted by InvestingPro, may provide some support, but the market's reaction to the guidance and the insider sale will be closely watched in the coming sessions.